miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer

Trastuzumab is established as standard care for patients with HER2-positive breast cancer both in the adjuvant and metastatic setting. However, 50% of the patients do not respond to the trastuzumab therapy, and therefore new predictive biomarkers are highly warranted. MicroRNAs (miRs) constitute a n...

Descripción completa

Detalles Bibliográficos
Autores principales: Nielsen, Boye Schnack, Balslev, Eva, Poulsen, Tim Svenstrup, Nielsen, Dorte, Møller, Trine, Mortensen, Christiane Ehlers, Holmstrøm, Kim, Høgdall, Estrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133651/
https://www.ncbi.nlm.nih.gov/pubmed/25177545
http://dx.doi.org/10.3389/fonc.2014.00207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133651/
https://www.ncbi.nlm.nih.gov/pubmed/25177545
http://dx.doi.org/10.3389/fonc.2014.00207

Ejemplares similares